🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million instances each year. Particularly high rates are observed in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on data published in a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which uses two antibiotics. The trial included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in many regions with limited resources.

Doctors directly involved have shared positive views. Having a one-pill regimen such as this is seen as a "game-changer" for public health efforts. This is viewed as crucial to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.